Dexmedetomidine May Delay Intubation in Patients With Severe COVID-19

Aim/Objective: Dexmedetomidine (DEX), a highly selective α2-adrenoceptor agonist, has sedative, analgesic, anxiolytic, and immunomodulatory properties that may provide benefits in critically ill patients with COVID-19. This study aimed to evaluate the effect of DEX on clinical outcomes in patients with severe COVID-19 treated in the intensive care unit (ICU).